TABLE 1.
Cases of C. glabrata candidemiaa
| Case no. | Age (yr) | Underlying disease | Donor type | Day of candidemiab | Antifungal drugc |
|---|---|---|---|---|---|
| 1 | 54 | CML | MRD | 41 | Itraconazole (P) |
| 2 | 12 | MDS | MUD | 82 | Voriconazole (P) |
| 3 | 21 | AML | MUD | 92 | Voriconazole (P) |
| 4 | 41 | MM | MUD | 64 | Voriconazole (T) |
| 5 | 44 | HL | Autologous | 13 | Fluconazole (P) |
| 6 | 31 | MDS | MUD | 16 | Fluconazole (P) |
| 7 | 53 | NHL | MM-UD | 173 | Fluconazole (T) |
a
CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; AML, acute myelogenous leukemia; MM, multiple myeloma; HL, Hodgkin's lymphoma; NHL, non-Hodgkin's lymphoma; MRD, human leukocyte antigen (HLA)-matched related donor; MUD, HLA-matched unrelated donor; MM-UD, HLA-mismatched unrelated donor.
b
Relative to day of receipt of stem cells (day 0).
c
Antifungal drugs received prior to or during candidemia. P, administered as part of a preventative algorithm; T, administered for treatment of a prior infection.